Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

January 31, 2026

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

Blinatumomab will be bridged to conventional BUCY conditioning regimen.

OTHER

Conventional therapy

Control group will be given conventional BUCY conditioning regimen.

Trial Locations (1)

215000

RECRUITING

The first affiliated hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Zhongda Hospital

OTHER

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

The First People's Hospital of Changzhou

OTHER

collaborator

Wuxi People's Hospital

OTHER

collaborator

First Affiliated Hospital of Wannan Medical College

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER